Thermic Sciences International
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Raymond C. Dabney
- Sector
- Basic Materials
- Industry
- Chemicals - Specialty
- Address
- 2910 North Powers Boulevard Colorado Springs CO United States of America 80922
- IPO Date
- Feb 1, 1995
- CIK
- 0000054424
- Website
- omnicanna.com
- Similar Companies
- Business
- Thermic Sciences International Corp (OTC: ENDO) develops and sells hemp-based health and wellness products, including cosmeceuticals such as Hempery miracle oil, Hemp milk body wash, Hemp lotion bars, Hemp rose soap, and Hemtastique lip and body balms; nutraceuticals; and food brands like HempTasty spices and sauces under its Hempery and HempTasty brands, alongside Thermic brand heating products comprising Thermic Heating Paint and Portable Thermic Heating Units. The company also pursues cannabinoid drug development targeting ailments including HIV/AIDS, asthma, cancer, glaucoma, influenza, pain management, and post-traumatic stress disorder, while operating as a conglomerate special purpose acquisition company focused on education, job creation, and diversified ventures such as digital immersion hubs and banking services. Founded in 1969 and headquartered in Colorado Springs, Colorado, Thermic Sciences International distributes its offerings across the United States, Canada, Colombia, Ireland, India, China, Japan, South Korea, and Afghanistan via online platforms and retail stores; it owns subsidiaries including Cannabis Science Inc. and Thermic Coating Systems Ltd., and was formerly known as OmniCanna Health Solutions, Inc. Recent developments include the acquisition of UK-based VIPOnline Ltd. to establish a Thermic Banking System integrating traditional and cryptocurrency services, progress toward completing the acquisition of Cannabis Science Inc. with uplisting efforts via Form 10 Registration Statement filing, and launches of infrared portable heaters alongside prototypes for Seebeck-based solid-state ceramic renewable battery power applications.
Crinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025
Aspect Biosystems Presents New Preclinical Data on Adrenal Bioprinted Tissue Therapeutics at ENDO 2025
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025
Marea Therapeutics Announces Oral Presentation Related to Acromegaly Program at ENDO 2025
ENDO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Endo, Inc. - NDOI
ENDO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Endo, Inc. - NDOI
ENDO ANNOUNCES CEO TRANSITION
ENDO REPORTS SECOND-QUARTER 2024 FINANCIAL RESULTS
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024